Plain-language summary of research published in the Georgian Medical Journal. Written for the general public by the GMJ News editorial team.
For decades, multiple sclerosis research focused on immune cells invading the brain from outside. A review in the Georgian Medical Journal turns attention to the immune cells already living inside the brain: microglia — and the growing evidence that they drive MS progression and could be its next therapeutic target.
What Are Microglia?
Microglia are the brain’s resident immune cells — its permanent security and maintenance staff. In health, they prune unused neural connections, clear debris, and watch for infection. In multiple sclerosis, they become central actors in the disease: activated microglia can attack the myelin insulation around nerve fibres, sustain chronic smouldering inflammation, and mark the expanding edges of MS lesions.
The Two Faces of Microglia
The review examines the crucial paradox: microglia are both villains and potential heroes. In harmful states they perpetuate inflammation and neurodegeneration — this “smouldering” microglial activity is now believed to drive the slow disability accumulation of progressive MS, the form that current drugs treat poorly. But microglia also have protective modes, in which they clear myelin debris and actively support remyelination — the repair process MS medicine desperately wants to unlock.
The Therapeutic Frontier
This dual nature defines the strategy the review maps: not destroying microglia, but modulating them — pushing them from damaging states into reparative ones. Multiple drug candidates targeting microglial signalling pathways are moving through research pipelines, aiming precisely at the progressive disease phase where today’s immunotherapies fall short.
Why It Matters
MS affects millions worldwide, typically striking young adults. Treatments that could slow progression and promote repair — rather than only preventing relapses — would transform lives. Understanding microglia is how medicine gets there.
Read the Original Research
Original article: Microglia in multiple sclerosis: pathogenesis and therapeutic modulation
Authors: Iryna Marazha, Daria Nazarova, Yuliia Barbashova
Published in: Georgian Medical Journal, Vol. 1 No. 2 (2026) — Health Systems Performance and Quality of Care
DOI: 10.66636/gmj.v1.i2.a40
📄 Read the full article at gmj.ge →
Georgian Medical Journal (GMJ) · ISSN 3088-4322 · gmj.ge · Open Access CC BY 4.0 · Published by the Public Health Institute of Georgia (PHIG). This summary is an independent editorial product of GMJ News; for clinical decisions, consult the original peer-reviewed article and a qualified professional.
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
